AR081874A1 - Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) - Google Patents

Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)

Info

Publication number
AR081874A1
AR081874A1 ARP110102043A ARP110102043A AR081874A1 AR 081874 A1 AR081874 A1 AR 081874A1 AR P110102043 A ARP110102043 A AR P110102043A AR P110102043 A ARP110102043 A AR P110102043A AR 081874 A1 AR081874 A1 AR 081874A1
Authority
AR
Argentina
Prior art keywords
patient
msh3
expression
cells
genotoxic
Prior art date
Application number
ARP110102043A
Other languages
English (en)
Inventor
Minoru Koi
Ajay Goel
C Richard Boland
Masanobu Takahashi
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR081874A1 publication Critical patent/AR081874A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para tratar un paciente que se halla en riesgo de contraer cáncer colorrectal o al que se le ha diagnosticado cáncer colorrectal. El método de la presente permite determinar la expresión general de MSH3 en células sospechadas de ser células de cáncer colorrectal del paciente y predecir la eficacia potencial de una terapia con un agente anti-neoplásico genotóxico en el tratamiento del paciente, donde una disminución en la expresión general de MSH3 en las células del paciente, en comparación con la expresión de MSH3 en las células colorrectales normales, es indicativa de una predisposición a la respuesta a la terapia con el agente antineoplásico genotóxico, donde la terapia comprende administrarles una cantidad eficaz del agente antineoplásico genotóxico a los pacientes, tal como inhibidores de la poli(adenosina-difosfato-ribosa)polimerasa o PARP y drogas de platino.
ARP110102043A 2011-02-12 2011-06-10 Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) AR081874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161442192P 2011-02-12 2011-02-12

Publications (1)

Publication Number Publication Date
AR081874A1 true AR081874A1 (es) 2012-10-24

Family

ID=46621117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102043A AR081874A1 (es) 2011-02-12 2011-06-10 Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)

Country Status (9)

Country Link
US (1) US20120207856A1 (es)
JP (1) JP2012165736A (es)
KR (1) KR20120093049A (es)
CN (1) CN102636648A (es)
AR (1) AR081874A1 (es)
AU (1) AU2011202823C1 (es)
BR (1) BRPI1103285A2 (es)
CA (1) CA2742342A1 (es)
MX (1) MX2011008748A (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531240A (ja) * 2012-10-09 2015-11-02 ファイブ３・ジェノミクス・エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ 腫瘍クローン性解析のためのシステムおよび方法
CA2891667A1 (en) 2012-11-16 2014-05-22 Calithera Biosciences Inc. Heterocyclic glutaminase inhibitors
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
CN112592975A (zh) * 2013-09-23 2021-04-02 芝加哥大学 关于dna损伤制剂用于癌症治疗的方法和组合物
EA036001B1 (ru) * 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
EP3174984B1 (en) * 2014-07-31 2020-05-06 Academia Sinica Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
CN104887680A (zh) * 2015-05-08 2015-09-09 胡继承 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途
EP3594343B1 (en) 2015-07-23 2021-04-21 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10258619B2 (en) 2015-10-05 2019-04-16 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
CN108449995B (zh) 2015-11-06 2022-02-01 文塔纳医疗系统公司 代表性诊断
PL3214222T3 (pl) 2016-03-02 2018-10-31 Joseph Vögele AG Zestaw montażowy belki równającej i sposób jej eksploatacji
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
BR112020006286A2 (pt) 2017-09-30 2020-10-20 Tesaro, Inc. terapias de combinação para tratamento do câncer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
CN111801117A (zh) * 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
WO2021037978A1 (en) * 2019-08-28 2021-03-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of cancer
CN113667750B (zh) * 2021-08-11 2022-05-17 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一种用于结直肠癌诊断的circRNA标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2550614T3 (es) * 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
CN101238373A (zh) * 2005-08-19 2008-08-06 因迪维姆德有限公司 内质蛋白片段及其衍生物作为结肠直肠腺瘤和/或癌的生物标记的用途；用于检测的方法和测试系统
AU2007325900A1 (en) * 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
US7618992B2 (en) * 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
US8067178B2 (en) * 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy

Also Published As

Publication number Publication date
MX2011008748A (es) 2012-08-31
CA2742342A1 (en) 2012-08-12
AU2011202823B2 (en) 2012-12-13
BRPI1103285A2 (pt) 2013-11-05
AU2011202823C1 (en) 2013-05-16
JP2012165736A (ja) 2012-09-06
US20120207856A1 (en) 2012-08-16
AU2011202823A1 (en) 2012-08-30
KR20120093049A (ko) 2012-08-22
CN102636648A (zh) 2012-08-15

Similar Documents

Publication Publication Date Title
AR081874A1 (es) Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
Owonikoko et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)
MX2015014486A (es) Marcadores de respuesta de células tumorales a la terapia.
BR112017011536A2 (pt) terapias de combinação
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
CY1123043T1 (el) Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
Teoh et al. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR079057A1 (es) Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca
DK2903616T3 (da) Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BR112016007100A2 (pt) tratamento contra tumor combinado usando interferon gama e minicélulas carregadas com fármaco dirigidas a ligantes biespecíficos
Kairevičė et al. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II–III resectable rectal cancer: 5-year survival data of a randomized controlled trial
Mamon et al. A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: cancer and Leukemia Group B (CALGB) 80003
BR112017009845A2 (pt) dianidrogalactitol juntamente com radiação para tratar carcinoma de célula não pequena dos pulmões e glioblastoma multiforme
CL2023003003A1 (es) Tratamiento y diagnóstico de trastornos inflamatorios
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
Yang et al. Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.

Legal Events

Date Code Title Description
FB Suspension of granting procedure